Panacea Biotec has received a confirmed work order valued at ₹78.24 crore from the United Nations International Children's Emergency Fund (UNICEF). The scope of the contract is the supply of bivalent Oral Polio Vaccine (bOPV) during Calendar Year 2028, subject to applicable conditions. The filing was disclosed to the exchange on 04 August 2026.

Order in Financial Context

The ₹78.24 crore order value represents approximately 46% of the company's average quarterly revenue of ₹169.02 crore. The total disclosed order book represents 0.00 quarters of average quarterly revenue coverage, based on the 0 orders disclosed across the last 3 fiscal quarters shown in the table below. This indicates that the current backlog is minimal relative to the company's run-rate, making this single order a significant near-term revenue contributor once execution begins.

Company Order Track Record

There are no previous order disclosures found for this company in the last three fiscal quarters. Consequently, there is no historical velocity data to compare against this recent win. The absence of prior disclosures suggests either a lack of reportable orders above the regulatory threshold or a gap in disclosure frequency during this period.

Execution and Revenue Quality

The company has shown mixed execution quality over the last three quarters. Revenue has grown sequentially from ₹150.20 crore in Q2FY26 to ₹172.00 crore in Q4FY26. However, profitability remains volatile. Q2FY26 saw a significant net loss of ₹14.00 crore with an OPM of -12.61%, while Q3FY26 returned to profit with ₹3.90 crore net profit and 7.11% OPM. Q4FY26 recorded a small net loss of ₹1.00 crore despite positive operating profit of ₹2.60 crore.

Revenue Growth — Order Wins Translating to Revenue

As Panacea Biotec has sustained order wins, its annual revenue has grown from ₹579.80 crore in FY25 to ₹639.77 crore in FY26, representing a YoY growth of +10.3% based on the latest annual data. Despite this top-line growth, the company posted a net loss of ₹7.80 crore in FY26, compared to a loss of ₹8.70 crore in FY25, indicating that revenue expansion has not yet translated into bottom-line recovery.

Working Capital and Execution Capacity

The balance sheet shows a current ratio of 1.47x and Total Liabilities/Equity of 0.51x, suggesting adequate short-term liquidity to fund operations. However, operating cashflow was negative at -₹27.40 crore in FY25, driven by high capex of -₹50.30 crore. This negative free cashflow of -₹77.70 crore indicates that the company is investing heavily in capacity or working capital, which may pressure liquidity if revenue collection lags.

Key Observations

• Margin stress: Net loss of ₹1.00 crore in Q4FY26; execution stress visible in quarterly data despite positive operating profit.
• Valuation check (as of 05 Aug 2026): P/E of -358.2x against ROCE of -0.44%. At the time of this article, valuation was pricing in execution improvement not yet visible in return ratios. (P/E is price-derived and will change; ROCE is from audited financials)
• Cash conversion: Operating cashflow of -₹27.40 crore in FY25; backlog is not converting to cash efficiently, and receivables or working capital cycle may be stretched.

What to Watch

• Execution timeline: Monitor the commencement of bOPV supply in Calendar Year 2028 to assess revenue recognition timing.
• Margin trajectory: Watch if the new order improves OPM, given the volatile margins seen in recent quarters (-12.61% to 7.11%).
• Cash conversion: Negative operating cashflows in FY25 require monitoring to ensure working capital cycles do not stretch further.
• Client concentration: With no other disclosed orders, UNICEF currently represents 100% of the visible order book, creating high client concentration risk.

Panacea Biotec Limited disclosed on July 24, 2026, that its wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL), has received a show cause notice from the Goods and Services Tax authority in Delhi. The notice, issued under Section 73 of the Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017, alleges an excess claim of Input Tax Credit (ITC) in the annual return filed for Financial Year 2022-23. The total liability demanded is ₹4.06 crore, which includes tax, interest, and penalty. This development requires shareholder attention as it represents a potential contingent liability, although the company states it does not foresee adverse operational impact.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The show cause notice was dated July 23, 2026, and was issued by the office of the Assistant Commissioner, GST, Delhi. The matter is currently at the show cause notice stage, with no penalty or restriction imposed yet.

Breakdown of Alleged Liability

The notice specifies a total financial demand of ₹4.06 crore. This amount is structured across three components: principal tax, interest accrued, and a penalty for the alleged non-compliance. The details are outlined below:

Company Response and Next Steps

Panacea Biotec Pharma Limited is currently collating relevant details to prepare a draft reply against the notice. The company asserts that it does not foresee any adverse impact on its financial, operational, or other activities arising from this show cause notice. No further action has been taken by the listed entity beyond initiating the response preparation process.

What the Numbers Show

The composition of the ₹4.06 crore liability reveals that interest constitutes a significant portion of the demand, accounting for approximately 38% of the total amount. The penalty component is relatively minor at ₹0.23 crore, suggesting the primary focus of the authority is on recovering the principal tax and associated statutory interest rather than imposing punitive measures at this stage. The allegation pertains specifically to FY22-23, indicating a retrospective review of input tax credit claims rather than a current-period compliance issue.